130066-24-9

Basic information

• Product Name: N-(4-TRIFLUOROMETHYL-PHENYL)-GUANIDINE
• Synonyms: N-(4-TRIFLUOROMETHYL-PHENYL)-GUANIDINE
• CAS NO: 130066-24-9
• Molecular Formula: C₈H₈F₃N₃
• Molecular Weight: 203.16
• Mol File: 130066-24-9.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 238.5±50.0 °C(Predicted)
• Appearance: /
• Density: 1.39±0.1 g/cm3(Predicted)
• PKA: 10.17±0.10(Predicted)
• CAS DataBase Reference: N-(4-TRIFLUOROMETHYL-PHENYL)-GUANIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-TRIFLUOROMETHYL-PHENYL)-GUANIDINE(130066-24-9)
• EPA Substance Registry System: N-(4-TRIFLUOROMETHYL-PHENYL)-GUANIDINE(130066-24-9)

Safety Data

• Hazardous Substances Data: 130066-24-9(Hazardous Substances Data)

Usage

General Description

N-(4-trifluoromethyl-phenyl)-guanidine is a chemical compound with the molecular formula C8H8F3N3. It is a guanidine derivative that is used in the synthesis of pharmaceuticals and organic compounds. N-(4-TRIFLUOROMETHYL-PHENYL)-GUANIDINE is a white solid at room temperature and is soluble in organic solvents such as acetone and ethanol. It is often used as a reagent in organic chemistry reactions, particularly in the formation of carbon-nitrogen bonds. N-(4-trifluoromethyl-phenyl)-guanidine has also been studied for its potential use in medicinal chemistry, as it may have applications in drug discovery and development. Overall, N-(4-trifluoromethyl-phenyl)-guanidine is an important and versatile compound in the field of organic and medicinal chemistry.

Upstream product

• 455-14-1 4-trifluoromethylphenylamine 
• 420-04-2 CYANAMID 
• 29671-92-9 chloroformamidine hydrochloride 

Relevant articles and documents

Discovery of CDK5 Inhibitors through Structure-Guided Approach

Specific abrogation of cyclin-dependent kinase 5 (CDK5) activity has been validated as a viable approach for the development of anticancer agents. However, no selective CDK5 inhibitor has been reported to date. Herein, a structure-based in silico screenin

One-Pot Evolution of Ageladine A through a Bio-Inspired Cascade towards Selective Modulators of Neuronal Differentiation

A bio-inspired cascade reaction has been developed for the construction of the marine natural product ageladine A and a de novo array of its N1-substituted derivatives. This cascade features a 2-aminoimidazole formation that is modeled after an arginine post-translational modification and an aza-electrocyclization. It can be effectively carried out in a one-pot procedure from simple anilines or guanidines, leading to structural analogues of ageladine A that had been otherwise synthetically inaccessible. We found that some compounds out of this structurally novel library show a significant activity in modulating the neural differentiation. Namely, these compounds selectively activate or inhibit the differentiation of neural stem cells to neurons, while being negligible in the differentiation to astrocytes. This study represents a successful case in which the native biofunction of a natural product could be altered by structural modifications.

N-phenyl-4-pyrazolo[1,5-6]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular efficacy

Glycogen synthase kinase 3 regulates glycogen synthase, the rate-determining enzyme for glycogen synthesis. Liver and muscle glycogen synthesis is defective in type 2 diabetics, resulting in elevated plasma glucose levels. Inhibition of GSK-3 could potentially be an effective method to control plasma glucose levels in type 2 diabetics. Structure-activity studies on a N-phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine series have led to the identification of potent and selective compounds with good cellular efficacy. Molecular modeling studies have given insights into the mode of binding of these inhibitors. Since the initial leads were also potent inhibitors of CDK-2/CDK-4, an extensive SAR was performed at various positions of the pyrazolo[1,5-b] pyridazin core to afford potent GSK-3 inhibitors that were highly selective over CDK-2. In addition, these inhibitors also exhibited very good cell efficacy and functional response. A representative example was shown to have good oral exposure levels, extending their utility in an in vivo setting. These inhibitors provide a viable lead series in the discovery of new therapies for the treatment of type 2 diabetes.